Successful Treatment with Azacitidine for the Simultaneous Occurrence of Multiple Myeloma and Acute Myeloid Leukemia with Concomitant Del(5q) and the JAK2 V617F Mutation

Overview

Journal Ann Hematol

Specialty Hematology

Date 2017 Jun 4

PMID 28577044

Citations 3

Authors

Satoko Oka

Kazuo Ono

Masaharu Nohgawa

Affiliations

Soon will be listed here.

Citing Articles

The Role of Epigenetics in the Development and Progression of Multiple Myeloma.

Ismail N, Mussa A, Zakaria N, Al-Khreisat M, Zahidin M, Ramli N Biomedicines. 2022; 10(11).

PMID: 36359286 PMC: 9687797. DOI: 10.3390/biomedicines10112767.

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.

Berthon C, Nudel M, Boyle E, Goursaud L, Boyer T, Marceau A Leuk Res Rep. 2020; 13:100202.

PMID: 32373459 PMC: 7191213. DOI: 10.1016/j.lrr.2020.100202.

Downregulation of DACT-2 by Promoter Methylation and its Clinicopathological Significance in Prostate Cancer.

Li S, Yin L, Huang K, Zhao Y, Zhang H, Cai C J Cancer. 2019; 10(7):1755-1763.

PMID: 31205531 PMC: 6548005. DOI: 10.7150/jca.28577.

References

Khong T, Sharkey J, Spencer A . The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008; 93(6):860-9. DOI: 10.3324/haematol.12261. View

Eskazan A, Ongoren S, Ar M, Soysal T, Ferhanoglu B, Aki H . Essential thrombocythemia and multiple myeloma: two rare diseases in one patient. Clin Lymphoma Myeloma Leuk. 2011; 11(5):442-5. DOI: 10.1016/j.clml.2011.04.001. View

Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M, Nakagawa H . International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol. 2001; 115(2):309-12. DOI: 10.1046/j.1365-2141.2001.03073.x. View

Dimopoulos M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M . Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010; 24(10):1769-78. DOI: 10.1038/leu.2010.175. View

Mossner M, Jann J, Nowak D, Platzbecker U, Giagounidis A, Gotze K . Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia. 2016; 30(9):1956-9. DOI: 10.1038/leu.2016.111. View